Anthropic has acquired stealth biotech AI startup Coefficient Bio in a $400 million stock deal. The Information and Eric Newcomer first reported the acquisition, with sources close to the deal confirming to TechCrunch that it closed, though they wouldn’t comment on the price.
The purchase comes as the Claude AI maker pushes deeper into healthcare and life sciences. In October, Anthropic launched Claude for Life Sciences, a tool designed to help researchers make scientific discoveries.
What’s the news?
Coefficient Bio’s founders, Samuel Stanton and Nathan C. Frey, started the company just eight months ago. Both previously worked in computational drug discovery at Genentech’s Prescient Design unit.
The startup used AI to make drug discovery and biological research more efficient. The team of around 10 people will join Anthropic’s health and life sciences group.
Why does it matter?
This acquisition shows Anthropic is serious about competing in the healthcare AI space. The company gains:
- Experienced drug discovery talent from a major pharmaceutical company
- AI expertise specifically focused on biological research
- A ready-made team to expand its life sciences offerings
The $400 million price tag for an eight-month-old startup with 10 employees highlights how much value AI companies place on specialized talent and domain expertise.
The context
AI companies are racing to find applications beyond chatbots and coding assistants. Healthcare represents a massive opportunity, with potential applications in drug discovery, medical imaging, and clinical research.
Anthropic faces competition from OpenAI, Google, and other AI giants who are also targeting healthcare markets. The Coefficient Bio acquisition gives Anthropic specialized knowledge that could help it stand out in this crowded field.
The deal also reflects the broader trend of AI companies acquiring talent-rich startups rather than building expertise from scratch. With competition for AI researchers intense, buying entire teams has become an expensive but effective strategy.